Definium Therapeutics Inc. (NASDAQ:DFTX) is up 4.79% intraday at $44.15, sustaining follow-through buying after its DT120 Phase 3 Emerge trial met its primary endpoint with an 8.1-point placebo-adjusted MADRS improvement in major depressive disorder.

Key Highlights

• Definium Therapeutics is trading at $44.15, up 4.79% intraday, peaking near $44.54 as investors digest the landmark Phase 3 MDD readout announced on June 22, 2026.

• The Emerge trial met its primary endpoint with a placebo-adjusted MADRS improvement of 8.1 points at week six, versus -13.3 points for DT120 against -5.2 points for placebo.

• DT120 ODT is a lysergide formulation, positioning Definium as a potential first commercially cleared psychedelic-assisted psychiatry treatment in the US.

• A major institutional research firm raised its price target to $57 and reiterated an Outperform rating following the data, implying nearly 30% upside from current levels.

Follow-Through Buying Sustains Post-Catalyst Momentum

Definium Therapeutics Inc. (NASDAQ:DFTX), a New York-based late-stage biopharmaceutical company developing treatments for psychiatric and neurological disorders, is up 4.79% intraday at $44.15. The stock peaked near $44.54, reflecting continued institutional positioning following the landmark Phase 3 data readout on June 22, 2026. Today's session represents follow-through accumulation as buy-side participants establish exposure at post-catalyst prices.

Emerge Trial: What the Data Shows

On June 22, 2026, Definium announced positive topline findings from its Emerge trial, a Phase 3 randomised, double-blind, placebo-controlled study evaluating a single dose of DT120 ODT 100 micrograms in adults with major depressive disorder. The trial met its primary endpoint with a placebo-adjusted improvement of 8.1 points on the MADRS scale at week six. Participants on DT120 showed a mean change of -13.3 points versus -5.2 points for placebo, a clinically meaningful difference that exceeds standard antidepressant trial benchmarks by a significant margin.

DT120 ODT is a lysergide formulation. No currently approved single-dose psychedelic treatment for major depressive disorder exists in the US market, making a positive Phase 3 result a potentially landmark entry in psychedelic-assisted psychiatry.

Regulatory Pathway and Analyst Reaction

The Phase 3 success positions Definium to engage with the FDA on a New Drug Application pathway for DT120 in major depressive disorder. A major institutional research firm raised its price target to $57 and reiterated an Outperform rating, implying nearly 30% upside from the current intraday level. Investor attention will now shift to the NDA filing timeline, safety database completion, and any risk evaluation and mitigation strategy requirements for a psychedelic-mechanism drug.

If approved, DT120 would enter a large and underserved market. A single-administration treatment with durable response data commands substantially higher per-patient revenue than chronic oral therapies, supporting a premium commercial pricing argument.